16951236

Source:http://linkedlifedata.com/resource/pubmed/id/16951236

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0013227, umls-concept:C0031327, umls-concept:C0205909, umls-concept:C1280500
pubmed:issue	17
pubmed:dateCreated	2006-9-4
pubmed:abstractText	Procarbazine hydrochloride (PCB) is one of the few anticancer drugs with activity against high-grade gliomas. This study was conducted to determine if the maximum tolerated dose and pharmacokinetics of PCB are affected by the concurrent use of enzyme-inducing antiseizure drugs (EIASD).
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/P30-CA0516, http://linkedlifedata.com/resource/pubmed/grant/U01-CA62406, http://linkedlifedata.com/resource/pubmed/grant/U01-CA62475
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9502500
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Anticonvulsants, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Procarbazine
pubmed:status	MEDLINE
pubmed:month	Sep
pubmed:issn	1078-0432
pubmed:author	pubmed-author:AlaviJane BJB, pubmed-author:BatchelorTracy TTT, pubmed-author:CarsonKathryn AKA, pubmed-author:FisherJoy DJD, pubmed-author:GrossmanStuart ASA, pubmed-author:HammourTarekT, pubmed-author:LesserGlennG, pubmed-author:MikkelsenTomT, pubmed-author:PhuphanichSurasakS, pubmed-author:SupkoJeffrey GJG
pubmed:issnType	Print
pubmed:day	1
pubmed:volume	12
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	5174-81
pubmed:meshHeading	pubmed-meshheading:16951236-Administration, Oral, pubmed-meshheading:16951236-Adult, pubmed-meshheading:16951236-Aged, pubmed-meshheading:16951236-Anticonvulsants, pubmed-meshheading:16951236-Antineoplastic Agents, pubmed-meshheading:16951236-Cohort Studies, pubmed-meshheading:16951236-Disease Progression, pubmed-meshheading:16951236-Dose-Response Relationship, Drug, pubmed-meshheading:16951236-Drug Administration Schedule, pubmed-meshheading:16951236-Enzyme Induction, pubmed-meshheading:16951236-Female, pubmed-meshheading:16951236-Follow-Up Studies, pubmed-meshheading:16951236-Glioma, pubmed-meshheading:16951236-Humans, pubmed-meshheading:16951236-Male, pubmed-meshheading:16951236-Maximum Tolerated Dose, pubmed-meshheading:16951236-Middle Aged, pubmed-meshheading:16951236-Procarbazine, pubmed-meshheading:16951236-Spectrometry, Mass, Electrospray Ionization, pubmed-meshheading:16951236-Time Factors, pubmed-meshheading:16951236-Treatment Outcome
pubmed:year	2006
pubmed:articleTitle	The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride.
pubmed:affiliation	The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231-1000, and Massachusetts General Hospital, Boston, USA. grossman@jhmi.edu
pubmed:publicationType	Journal Article, Clinical Trial, Research Support, N.I.H., Extramural